爾康製藥(300267.SZ):氧化鋅、尿素、阿莫西林等原料藥通過藥品GMP現場檢查
格隆匯 8 月 20日丨爾康製藥(300267.SZ)公佈,近日,公司收到湖南省藥品監督管理局下發的《關於藥品GMP檢查結果的通知》,公司的原料藥品種氧化鋅、尿素、膽茶鹼、鹽酸溴己新、硫酸銅、硝酸銀、亞硝酸鈉、依託紅黴素、高錳酸鉀、阿莫西林和甲醛溶液符合《藥品生產質量管理規範》要求。
公司本次通過藥品GMP合規性檢查,表明公司上述原料藥品種已獲得生產資質,對公司未來穩健發展有積極推動作用。公司將根據市場需求情況進行生產和銷售,並確保良好的生產管理和質量保證體系。本次獲得《關於藥品GMP檢查結果的通知》不會對公司業績產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.